↓ Skip to main content

S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial

Overview of attention for article published in BMC Cancer, December 2013
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
46 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial
Published in
BMC Cancer, December 2013
DOI 10.1186/1471-2407-13-583
Pubmed ID
Authors

Yong Wha Moon, Soohyeon Lee, Byeong-Woo Park, Eun-Kyung Kim, Seung Il Kim, Ja Seung Koo, Seho Park, Min Jung Kim, Hyun Cheol Chung, Joo-Hang Kim, Joohyuk Sohn

Abstract

This study evaluated the efficacy and safety of S-1 combined with docetaxel (SD) following doxorubicin plus cyclophosphamide (AC) as neoadjuvant therapy in patients with HER2-negative, stage II-III breast cancer.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Ecuador 2 4%
United States 1 2%
Unknown 43 93%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 7 15%
Researcher 6 13%
Student > Ph. D. Student 4 9%
Student > Doctoral Student 4 9%
Other 3 7%
Other 9 20%
Unknown 13 28%
Readers by discipline Count As %
Medicine and Dentistry 19 41%
Nursing and Health Professions 4 9%
Pharmacology, Toxicology and Pharmaceutical Science 3 7%
Agricultural and Biological Sciences 3 7%
Biochemistry, Genetics and Molecular Biology 2 4%
Other 1 2%
Unknown 14 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 December 2013.
All research outputs
#20,211,690
of 22,733,113 outputs
Outputs from BMC Cancer
#6,489
of 8,272 outputs
Outputs of similar age
#266,897
of 306,486 outputs
Outputs of similar age from BMC Cancer
#86
of 107 outputs
Altmetric has tracked 22,733,113 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,272 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 306,486 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 107 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.